Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: Ready for prime time?

Clinical Neuropharmacology

Volumn 31, Issue 2, 2008, Pages 104-119

  Deutsch, Stephen I ^a   Rosse, Richard B ^b   Mastropaolo, John ^b   Long, Katrice D ^b   Gaskins, Brooke L ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NONE

Author keywords

Chromatin; Depression; Epigenetic; Histone; Huntington disease; Promoters; Schizophrenia; Transcription

Indexed keywords

ACETYL COENZYME A; ARYLBUTYRIC ACID DERIVATIVE; ATROPHIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA METHYLTRANSFERASE 1; FLUOXETINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; POLYGLUTAMINE; PROTEIN; REELIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

AMYOTROPHIC LATERAL SCLEROSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG TARGETING; EPIGENETICS; FRAGILE X SYNDROME; GENE CONSTRUCT; GENE EXPRESSION REGULATION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MAJOR DEPRESSION; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES;

EID: 41749090056     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318067e255     Document Type: Review

References (29)

1. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005;40:1-13.
2. Akbarian S, Ruehl MG, Bliven E, et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2005;62:829-840.
3. Verdone L, Caserta M, Mauro ED. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005;83:344-353.
4. Sharma RP. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 2005;72:79-90.
5. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deactylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003;100:2041-2046.
6. Colvis CM, Pollock JD, Goodman RH, et al. Epigenetic mechanisms and gene networks in the nervous system J Neurosci. 2005;25:10379-10389.
7. Szyf M, Weaver ICG, Champagne FA, et al. Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat. Front Neuroendocrinol 2005;26:139-162.
8. Mitchell CP, Chen Y, Kundakovic M, et al. Histone deacetylase inhibitors decrease reelin promoter methylation in vitro. J Neurochem 2005;93:483-492.
9. Tremolizzo L, Carboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 2002;99:17095-17100.
10. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000;97:6763-6768.
11. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-9427.
12. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-743.
13. Gardian G, Browne SE, Choi D-K, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005;280:556-563.
14. Ying M, Xu R, Wu X, et al. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 2006;281:12580-12586.
15. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004;13:1183-1192.
16. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93:1087-1098.
17. Issidorides MR, Stefanis CN, Varsou E, et al. Altered chromatin ultrastructure in neutrophils of schizophrenics. Nature 1975;258:612-614.
18. Issidorides MR, Zioudrou C, Lykouras E, et al. Drug-induced changes in chromatin ultrastructure and nuclear basic proteins of the neutrophils of chronic schizophrenics. Prog Neuropsychopharmacol 1978;2:79-85.
19. Kosower NS, Gerad L, Goldstein M, et al. Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia. Am J Med Genet 1995;60:133-138.
20. Dong E, Agis-Balboa RC, Simonini MV, et al. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci U S A 2005;102:12578-12583.
21. Deutsch SI, Rosse RB, Lakshman RM. Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of Alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1369-1380.
22. Veldic M, Guidotti A, Maloku E, et al. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A 2005;102:2152-2157.
23. Simonini MV, Camargo LM, Dong E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A 2006;103:1587-1592.
24. Tsankova NM, Kumar A, Nestler EJ. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004;24:5603-5610.
25. Schroeder FA, Lin CL, Crusio WE, et al. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2006 (Epub ahead of print).
26. Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9:519-525.
27. Alarcon JM, Malleret G, Touzani K, et al. Chromatin acetylation, memory, and LTP are impaired in CBP ± mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004;42:947-959.
28. Ghosh NK, Deutsch SI, Griffin MJ, et al. Regulation of growth and morphological modulation of HeLa65 cells in monolayer culture by dibutyryl cyclic AMP, butyrate and their analogs. J Cell Physiol 1975;86:663-672.
29. Deutsch SI, Silvers DN, Cox RP, et al. Ultrastructural and enzymic modulation of HeLa cells induced by sodium butyrate and the effects of cytochalasin B and colcemid. J Cell Sci 1976;21: 391-406.